COMP <GO>
ABT vs LLY // REVENUE GROWTH (YOY)
Abbott Laboratories (NYSE) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: ABT 5
— LLY 10
▲ REVENUE GROWTH (YOY) LEADER: LLY
LAST: $106.20 (+1.56%) • MKT CAP: $180.95B
revenue-growth
5.70%
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
revenue-growth
45.51%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ABT VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ABT | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 56.40% | 83.64% | -27.24 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 11.90% | 32.36% | -20.46 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 18.4x | 36.4x | -18.02 | ABT | /valuation <GO> |
| Free Cash Flow Yield | 4.09% | 2.30% | +1.79 | ABT | /fcf-yield <GO> |
| Operating Margin | 18.20% | 40.21% | -22.01 | LLY | /operating-margins <GO> |
| Net Profit Margin | 14.70% | 31.90% | -17.20 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 5.70% | 45.51% | -39.81 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 2.27% | 0.49% | +1.78 | ABT | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.36 | 9.29 | -4.93 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 9/9 | -1.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.90% | 6.77% | +0.13 | LLY | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 59.5 | 77.9 | -18.36 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.99 | 0.51 | +0.48 | ABT | /macro-sensitivity <GO> |
| Forward P/E Multiple | 25.8x | 26.3x | -0.45 | ABT | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $180.95B | $1.33T | -$1.15T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ABT REV | LLY REV | ABT GROSS % | LLY GROSS % | ABT FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $44.33B | $65.18B | 56.4% | 83.0% | $7.39B | $16.81B |
| FY 2024 | $41.95B | $45.04B | 55.4% | 81.3% | $6.35B | $8.82B |
| FY 2023 | $40.11B | $34.12B | 44.0% | 79.3% | $5.46B | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ABT // BETA 0.99
LLY // BETA 0.51